Allogeneic CAR-T Cells: More than Ease of Access?

Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inabi...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Charlotte, Jozwik, Agnieszka, Pepper, Andrea, Benjamin, Reuben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210057/
https://www.ncbi.nlm.nih.gov/pubmed/30275435
http://dx.doi.org/10.3390/cells7100155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210057/
https://www.ncbi.nlm.nih.gov/pubmed/30275435
http://dx.doi.org/10.3390/cells7100155

Ejemplares similares